ROS1 and melanoma: A consistent finding seen in the TCGA melanoma population (HR 1.15, 95% CI 0.80–1.65; P = 0.463, Supplementary Figure 2) further confirmed that ROS1 mutation serves as a potential predictive biomarker of ICI treatment for melanoma, without affecting the prognosis of patients.